Biotechnology
The final days of 2025 delivered a devastating blow to Ultragenyx Pharmaceutical as the company lost over $1 billion in market value following the failure of its bone disease therapy setrusumab in two pivotal Phase III trials. The December 29 announcement that the drug failed to reduce fracture rates in
Biotechnology
AbbVie kicked off 2026 with a strategic bang, announcing a potentially $1.2 billion licensing deal with China's Suzhou Zelgen Biopharmaceuticals for exclusive rights to develop and commercialize alveltamig (ZG-006) outside of Greater China. The New Year's Eve agreement represents one of the largest T-cell engager
Biotechnology
FibroBiologics files IND application for CYPS317, marking the first fibroblast spheroid-based therapy to enter clinical development for psoriasis, with compelling preclinical data showing superior durability compared to existing biologic treatments.